Long-Term Cardiovascular Effects of Medications for Attention-Deficit/Hyperactivity Disorder-Balancing Benefits and Risks of Treatment.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Prescribing Practices, Motivations, and Behaviors Contributing to Prescription Stimulant Misuse Among Medical Students at an Allopathic Medical School: Cross-Sectional Survey Study.Cureus · 2026
   Article
2. Exploring the Association Between Attention-Deficit/Hyperactivity Disorder and Essential Hypertension in a Pediatric Population.Children (Basel, Switzerland) · 2026
   Article
3. Five Steps to Improve Cardiac Safety of Attention Deficit Hyperactivity Disorder Treatment.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2024
   Article
4. Subclinical attention-deficit hyperactivity disorder symptoms and unhealthy lifestyle behaviours.BJPsych open · 2024
   Article

Corrections and comments

• Comment on
  Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases.2024

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as